期刊
BIOACTIVE MATERIALS
卷 27, 期 -, 页码 58-71出版社
KEAI PUBLISHING LTD
DOI: 10.1016/j.bioactmat.2023.03.016
关键词
Microneedle; Controlled release; Melanoma; AIE; Photothermal therapy; Chemotherapy
Melanoma, the most aggressive form of skin cancer, is difficult to treat due to frequent drug administration and lack of direct monitoring of drug release. In this study, a self-monitoring microneedle-based drug delivery system was developed for light-controlled chemo-photothermal therapy of melanoma. The system utilized PATC microparticles that encapsulate both a chemotherapeutic drug and a photothermal agent, allowing for direct observation and verification of drug release under light stimuli.
Melanoma is the most aggressive and malignant form of skin cancer. Current melanoma treatment methods generally suffer from frequent drug administration as well as difficulty in direct monitoring of drug release. Here, a self-monitoring microneedle (MN)-based drug delivery system, which integrates a dissolving MN patch with aggregation-induced emission (AIE)-active PATC microparticles, is designed to achieve light-controlled pulsatile chemo-photothermal synergistic therapy of melanoma. The PATC polymeric particles, termed D/I@PATC, encapsulate both of chemotherapeutic drug doxorubicin (DOX) and the photothermal agent indocyanine green (ICG). Upon light illumination, PATC gradually dissociates into smaller particles, causing the release of encapsulated DOX and subsequent fluorescence intensity change of PATC particles, thereby not only enabling direct observation of the drug release process under light stimuli, but also facilitating verification of drug release by fluorescence recovery after light trigger. Moreover, encapsulation of ICG in PATC particles displays significant improvement of its photothermal stability both in vitro and in vivo. In a tumor-bearing mouse, the application of one D/I@PATC MN patch combining with two cycles of light irradiation showed excellent controllable chemophotothermal efficacy and exhibited similar to 97% melanoma inhibition rate without inducing any evident systemic toxicity, suggesting a great potential for skin cancer treatment in clinics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据